MNKD Mannkind Corp
Price (delayed)
$5.02
Market cap
$1.52B
P/E Ratio
50.2
Dividend/share
N/A
EPS
$0.1
Enterprise value
$1.77B
MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, its
Highlights
The equity has surged by 68% year-on-year and by 62% since the previous quarter
Mannkind's gross profit has soared by 53% YoY and by 9% from the previous quarter
Mannkind's quick ratio has decreased by 32% QoQ and by 14% YoY
Key stats
What are the main financial stats of MNKD
Market
Valuations
Earnings
Shares outstanding
303.59M
Market cap
$1.52B
Enterprise value
$1.77B
Price to earnings (P/E)
50.2
Price to book (P/B)
N/A
Price to sales (P/S)
4.83
EV/EBIT
25.78
EV/EBITDA
22.78
EV/Sales
6.19
Revenue
$285.5M
Gross profit
$208.9M
Operating income
$68.68M
Net income
$27.59M
EBIT
$68.5M
EBITDA
$77.54M
Free cash flow
$32.82M
Per share
Balance sheet
Liquidity
EPS
$0.1
EPS diluted
$0.1
Free cash flow per share
$0.12
Book value per share
-$0.29
Revenue per share
$1.04
TBVPS
$1.41
Total assets
$393.84M
Total liabilities
$472.66M
Debt
$289M
Equity
-$78.82M
Working capital
$186.47M
Debt to equity
-3.67
Current ratio
3.28
Quick ratio
2.56
Net debt/EBITDA
3.12
Margins
Efficiency
Dividend
EBITDA margin
27.2%
Gross margin
73.2%
Net margin
9.7%
Operating margin
24.1%
Return on assets
6.2%
Return on equity
N/A
Return on invested capital
9.9%
Return on capital employed
22%
Return on sales
24%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MNKD stock price
How has the Mannkind stock price performed over time
Intraday
1.41%
1 week
-0.79%
1 month
-5.99%
1 year
16.47%
YTD
-21.93%
QTD
-0.2%
Financial performance
How have Mannkind's revenue and profit performed over time
Revenue
$285.5M
Gross profit
$208.9M
Operating income
$68.68M
Net income
$27.59M
Gross margin
73.2%
Net margin
9.7%
Mannkind's gross profit has soared by 53% YoY and by 9% from the previous quarter
The revenue has grown by 43% YoY and by 7% from the previous quarter
Mannkind's net income has increased by 28% from the previous quarter
The company's net margin rose by 20% QoQ
Growth
What is Mannkind's growth rate over time
Valuation
What is Mannkind stock price valuation
P/E
50.2
P/B
N/A
P/S
4.83
EV/EBIT
25.78
EV/EBITDA
22.78
EV/Sales
6.19
The price to earnings (P/E) is 45% lower than the last 4 quarters average of 90.1
Mannkind's EPS has increased by 25% from the previous quarter
The equity has surged by 68% year-on-year and by 62% since the previous quarter
The P/S is 51% lower than the 5-year quarterly average of 9.8 and 21% lower than the last 4 quarters average of 6.0
The revenue has grown by 43% YoY and by 7% from the previous quarter
Efficiency
How efficient is Mannkind business performance
The ROA is up by 35% QoQ
The company's return on invested capital rose by 16% QoQ
Mannkind's ROS has increased by 5% from the previous quarter
Dividends
What is MNKD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MNKD.
Financial health
How did Mannkind financials performed over time
The company's total assets is 17% lower than its total liabilities
MNKD's total liabilities is down by 34% year-on-year and by 30% since the previous quarter
Mannkind's quick ratio has decreased by 32% QoQ and by 14% YoY
The debt to equity has dropped by 76% year-on-year and by 60% since the previous quarter
The equity has surged by 68% year-on-year and by 62% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.